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ABSTRACT 
Purpose 
There is equivocality regarding the interaction between vitamin D and insulin-like growth
factor-1 (IGF-1). Thus, the aim of this study was to elucidate the effect of vitamin D 
supplementation on serum levels of IGF-1 by conducting a systematic review and meta-
analysis of randomized controlled trials (RCTs). 
Methods 
PubMed, Scopus, and ISI Web of Science databases were searched up to May 2019 for RCTs 
that evaluated the effect of vitamin D supplementation on IGF-1 levels. Mean and standard
deviation changes of IGF-1 in each treatment group were considered for analysis and pooled
using random-effect model. Risk of bias for included studies was assessed by the Cochrane
scale and the NutriGrade approach was applied to evaluate the quality of evidence. 
Results 
Six trials (n= 773 participants) were included in the meta-analysis. Compared with control
group, vitamin D supplementation yielded no significant effect on serum level of IGF-1 
(weighted mean difference [WMD] = 4.66 ng/ml, 95% CIs: -6.72 to 16.03, P=0.42, I2= 74.8, P-
heterogeneity= 0.001). Additionally, no meaningful changes were observed in subgroup analyses. 
Conclusion 
The evidence from the limited number of published trials does not convincingly show that







     
 
quality studies are needed to reach a consensual conclusion in this area. 
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INTRODUCTION 
Insulin-like growth factor-1 (IGF-1) is produced by the liver and is considered as a growth
promoting peptide mediating growth hormone (GH) effects in the body (1, 2). Almost all
(around 99%) circulating IGF-1 is bound to the IGF binding protein (IGFBP), and potentially
inactive; while less than one percent of IGF-1 circulates unbound, which possesses an
important role in the promotion of cell proliferation, differentiation, migration, and inhibition
of cell apoptosis with a recognized effect on tumor development (3-5). Previous
epidemiological studies have provided some evidence for the associations of circulating IGF-
1 and progression of some tumors, including lung, esophageal, colorectal, prostate, ovarian and
breast cancers (4, 6-8). These cancers account for a significant proportion of cancer occurrence
worldwide; thus, investigating the factors affecting IGF-1 levels may help in the prevention or
treatment of cancers (9). 
Recently, a positive correlation has been reported between serum concentrations of IGF-1 and
vitamin D status in healthy subjects (10-12). Although no mechanistic study has yet addressed 
the effect of vitamin D on circulating IGF-1 (10), it seems that vitamin D promotes liver
production of IGF-1, IGF-1 receptors, and, likely, IGFBP3. Such effects are purported to occur
directly through binding to, and activating, the nuclear vitamin D receptor, thereby inducing 
transcription of relevant genes (10, 13), and through enhancing GH stimulation (10, 14, 15). 
According to in vitro experiments, hepatic non-parenchymal cells, such as stellate, Kupffer, 
and sinusoidal endothelial cells, because of their high expression of vitamin D receptor, are
target cells for vitamin D (16). Moreover, given intake of calcium is positively associated with 




   
    
     
    
     
 
   
   





      
         





increases in intestinal calcium absorption. Recent reviews have reported a relationship between 
total vitamin D intake and inhibition of apoptosis (18), which is believed to play a part in 
preventing some cancers (19, 20). However, numerous studies have failed to replicate such
results (21, 22). Therefore, the controversial role of vitamin D in cancer development may be
partly explained by the focus of the efficacy of vitamin D supplementation on IGF-1 as an
important mediator in the pathology of cancer. 
A number of randomized controlled trials (RCTs) have been conducted to infer the possible
effects of vitamin D supplementation on IGF-1 levels, yet results are bereft of uniformity. (10, 
23). Therefore, the aim of this study was to investigate whether vitamin D supplementation can 
affect IGF-1 levels in adults, conducting a systematic review and meta-analysis of RCTs. 
METHODS 
This systematic review was performed according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) guidelines (24) and was registered in the






      
   
      






       
            
        
      
       
       
            




      
         
A comprehensive search was undertaken through PubMed, Scopus, and ISI Web of Science
databases, up to May 2019 and without any language restriction. In order to find relevant 
articles, a combination of MESH and non-MESH terms related to “insulin-like growth factor-
1”, “vitamin D” and “study design” were used. Further details regarding the search strategy are
shown in Table S1. In addition, review articles and bibliographies were hand-searched to find
additional eligible studies. 
Eligibility criteria 
Two authors (FM and SH A) independently conducted the study selection based on the
inclusion and exclusion criteria. Original RCTs (either parallel or cross-over design) that were
investigated the effect of vitamin D supplementation (oral or injectable supplement) on 
serum levels of IGF-1 (as primary or secondary outcome) on adult human subjects, were
considered eligible for inclusion in the present meta-analysis. 
Trials were excluded if they; (i) were conducted using children or adolescent subjects, or on 
pregnant or lactating women, (ii) did not include a placebo group or non-exposed control, (iii)
used supplements as a placebo; and (iv) examined multiple interventions only. 
Data extraction 
The following information was extracted from each article: first author’s name, year of




     
         
       
           
     
       
        
       
    




        
       
       
            
         
               
   
  
        
status of the participants, number of participants in intervention and control groups, baseline 
serum levels of 25(OH)D, the length of the intervention, type and dose of vitamin D
supplement, measurement method of IGF-1 and mean and standard deviation (SD) of IGF-1 
before and after intervention or mean and SD of IGF-1 change during the follow-up period. If
data were insufficient for meta-analysis, relevant information was requested by contacting
the corresponding author (25, 26). Vitamin D supplementation homogenized as weekly dose
(15, 23, 27) and when multi-doses of vitamin D were administered in the trial, the highest
dose was included in the analysis (15, 27). Serum levels of IGF-1 in all trials were also
converted into ng/ml. Any disagreements were discussed and resolved via cooperative 
triangulation with the corresponding author (SS). 
Quality assessment 
Quality of eligible trials was assessed using the Cochrane risk of bias tool for RCTs (28). This
scale covers six domains of bias including selection bias, performance bias, detection bias,
attrition bias, reporting bias, and bias due to problems not covered elsewhere. These factors
were classified as low risk of bias, high risk of bias, or unclear. Studies with a low risk of bias
for all criteria were regarded as good quality; if one criterion not met or two criteria unclear,
the study was regarded as fair; and studies which two or more criteria listed as high risk of
bias were regarded as poor quality. 
Quality of meta-evidence 




       
       
     
      
  
        
     
            
          
        
         
        
   
     
             
          
             
      
     
          
           
      
based on the major domain of study limitations including the risk of bias, precision,
heterogeneity, directness, publication bias, funding bias and study design (29). The quality of 
evidence was categorized to high (≥ 8 points), moderate (6 to <8 points), low (4 to <6 points)
and very low (0 to <4 points) based on this scoring system. 
Statistical analyses 
This meta-analysis was performed using Stata software version 14 (Stata Corp. College Station,
Texas, USA). We used the mean difference (95% confidence intervals [CIs]) in IGF-1 levels
between the intervention (vitamin D supplementation) and placebo groups as the effect size
for the meta-analysis. When the SD of changes from baseline was missing, it was calculated
using standard errors and the formula provided in the Cochrane Handbook of Systematic
Reviews (30) (correlation R = 0.811) (15, 27). To evaluate whether the results of the studies 
were homogeneous, we used Cochran’s Q test (31) and the I-square statistic (I2) (32). In order
to determine the potential sources of heterogeneity, sensitivity, and subgroups analyses were
performed. Data were stratified into ten subgroups on the basis of study design, age of
participants (less than or equal to 65 and greater than 65 years old of age), duration of the 
intervention (less than or equal to 12 weeks and more than 12 weeks), type of vitamin D
supplement (vitamin D3 and vitamin D3+ D2), dose of vitamin D supplement (7000 IU/week or
less, and more than 7000 IU/week), baseline values of vitamin D (10-30 ng/ml and less than
10 ng/ml), method used for IGF-1 assessment (radioimmunoassay or chemiluminescence), 
quality of the studies (poor or fair), baseline values of body mass index (BMI) (< 25 kg/m2, 25
to < 30 kg/m2, and ≥30 kg/m2), latitude (< 50 magnetic latitude, 50 to <60 , and ≥60 magnetic




      
              
  
      
   
 
   
     
     
     
       
         
        
   
           
        
        
            
    
         
       
elderly or hypertensive disorder). Sensitivity analysis was conducted by excluding one study
or a group of studies at a time, to explore which study might influence the overall effect size. 
Publication bias was evaluated using the visual inception of funnel plots and confirmed
statistically by the Begg’s adjusted-rank correlation (33) and the Egger’s regression asymmetry
tests (34). Two-sided P values <0.05 were considered significant. 
RESULTS 
Study selection and characteristics 
The primary search yielded 2349 references, of which, 30 full-texts were assessed for inclusion 
in the present meta-analysis. The reason for exclusion of studies is presented in Figure 1. Eight
trials were initially considered suitable for inclusion in the systematic review (15, 23, 25-27, 
35-37). However, two trials were excluded because baseline values of IGF-1 levels in
intervention and control groups were not presented separately (25). or, only the serum levels
of IGF-1 as μg/10E06 platelets were reported (26). Finally, six trials were included in the meta-
analysis (15, 23, 27, 35-37).
The general characteristics of the six studies are outlined in Table 1. Studies were published
from 1994-2017 and were carried out in Italy (15), United States (36), Sweden (35), Finland
(37), Norway (27) and Australia (23), respectively. Participants included both men and women
in all trials (15, 23, 27, 35-37), and total sample size in the studies ranged from 39 to 318. 
Vitamin D regimens used in the trials ranged from 5000 to 85300 IU/week, whilst the duration 
of vitamin D administration varied from 8 to 52 weeks and all patients had oral treatment. All




       
     
         
      
   
 
      
 
       
           
       
       
        
         
     
         
 
        
      
      
subjects (≤30 ng/ml of serum 25(OH)vitamin D (23, 36). Trials enrolled participants with GH
deficiency (15), hyperparathyroidism (35), pre-diabetes (36), hypertension (23), overweight
and obesity (27) and one trial was also conducted on bedridden elderly (37). Vitamin D was 
used as cholecalciferol in five studies (15, 23, 27, 35, 36) and one trial used both
cholecalciferol and ergocalciferol (37). 
Risk of bias and quality of evidence
The overall quality of included trials was assessed and rated as “fair” (23, 35, 36) for three
trials, and “poor” (high risk of bias) for the remaining studies (15, 27, 37) (Table S2). All trials
were randomized (15, 23, 27, 35-37), although four of them did not explain the randomization
process (15, 27, 36, 37). Masking of treatment allocation was not considered in any trials, and
two trials were not blind in design (15, 37). All studies described details about withdrawal,
and all expected outcomes were presented in all but two trials (27, 37).
The NutriGrade score demonstrated moderate confidence in the effect estimate of the
vitamin D supplementation on IGF-1 (NutriGrade score= 7.05). (Table S3).
Meta-analysis 
In total, six trials (n= 773 participants) were included in the final analysis (15, 23, 27, 35-37).
Overall analysis revealed no significant effect of vitamin D supplementation on IGF-1 levels




        
         
       
        
  
        
      
  
       




       
         
        
   
   
    
      
      
however, between-study het erogeneity was high (Q statistic= 19.81, P= 0.001, I 2= 74.8%).
Subgroup analysis found the health status of participants, duration of vitamin D
supplementation and dose of vitamin D were potential sources of heterogeneity; however,
no meaningful changes were observed in any of the subgroups for IGF-1 levels (Table 2). 
Sensitivity analysis and publication bias 
The sensitivity analysis was performed using step by step exclusion of each study from the
analysis. Results from sensitivity analysis showed that omission of any one study from the
analysis did not alter the overall effect of vitamin D supplementation on serum levels of IGF-
1. There was no evidence of asymmetry in the Funnel plot, and Begg’s and Egger’s tests
confirmed this finding (Begg’s P= 0.85; Egger’s P= 0.49). 
DISCUSSION 
The present meta-analysis of six randomized controlled trials showed that vitamin D 
supplementation did not significant effect on serum levels of IGF-1. Moreover, no significant
changes were observed for IGF-1 levels in any of the subgroups.
Increased levels of IGF-1 have been suggested to contribute to the development of several 
types of tumor, which raises the possibility that the increase in serum IGF-1 following vitamin
D treatment may be detrimental in some cases (3, 5, 38). There is some putative hypotheses 
that the active vitamin D metabolite can regulate the actions of IGF-1 (39), however, a plausible 




        
      
 
      
           
      
      
       
   
       
        
     
    
    
      
       
       
     
      
       
    
 
D is most likely able to regulate IGF-1 concentrations by acting in the liver, because hepatic
cells are the main source of circulating IGF-1 (2). 
Although the results in several antecedent trials suggest that vitamin D treatment significantly
increases the serum levels of IGF-1 (10, 35), our meta-analysis did not support these findings,
which are in line with some prior reports (23, 26, 36). There is some explanation that may
influence our results. IGF-1 is mostly bound by one of the IGFBP members (40), therefore,
the concentrations of free IGF-1 are negatively correlated with IGFBP-1 and IGFBP-3 (41).
Vitamin D has been shown to mediate an increase in the production of IGFBP-3 and 
consequently decrease the IGF-1/IGFBP-3 ratio in some studies (42). So, the IGF-1/IGFBP-3 
ratio may be a more sensitive marker of metabolic efficacy of IGF-1, which corresponds with 
previous observations (27). However, we were unable to analyze this ratio because only two 
trials assessed IGFBP-1 (35) and IGF-1/IGFBP-3 ratio (27), therefore, this represents a
sensible avenue for future research.
Body weight is another factor that may affect IGF-1 levels. IGF-1 is originally synthesized in 
the liver, but is also found in other tissues like fat mass, where it’s expression is stimulated by
1,25(OH)2D (43). Studies have shown that IGF-1 is linked with BMI in a non-linear manner,
where individuals with extremely low and/or high BMI had lower levels of IGF-1 (44). Also, 
people with obesity are more likely to experience vitamin D deficiency, as compared to normal-
weight counterparts. It may be suggested that the lack of a notable increase in supplemental 
vitamin D in obese people may conceivably be attributed to their higher BMI, since excess 
adiposity dilutes supplemental vitamin D (45). Notwithstanding, however, we did not find any




      
             
    
     
    
  
 
    
 
      
 
 
     
    
       
   
  
   
          
         
        
Latitude is known as one of the main eco-environmental determinants of dermal
photosynthesis of vitamin D (46). It is believed that insufficient intensity of sunlight at higher
latitudes is the cause of decreasing circulating 25(OH)D concentrations (47). In the same way,
we found that vitamin D supplementation was marginally, yet significantly, associated with
lower levels of IGF-1 when analysis was restricted to studies conducted in higher latitudes. It
seems the small number of studies may explain the non-significant results; nevertheless,
detailed examination of eco-environmental determinants warrants further investigation. 
Our analysis also showed a marginal significant reduction in IGF-1 levels when vitamin D was 
administered in periods longer than 12 weeks. It has been suggested that vitamin D
supplementation has a time-dependent effect on IGF-1 levels (48); however, there were no
studies that monitored the effect of vitamin D supplementation on IGF-1 concentrations across 
several time points. 
Calcium, phosphate, and PTH are classical regulators of renal 1α -hydroxylase and, by
extension, the endocrine actions of vitamin D (10). In the present meta-analysis, regarding 
controlling for these regulators, four RCTs excluded patients with hypercalcemia (defined as
a plasma calcium concentration >2.65 mmol/L) (23, 27, 35, 37) and two adjusted for the 
outcome measurement (23, 35). However, several studies have not considered the regulatory 
effect of calcium, phosphate, and PTH on vitamin D action, respectively. 
To the best of our knowledge, this is the first meta-analysis of randomized controlled clinical 
trials to evaluate the effect of vitamin D supplementation on serum levels of IGF-1 across




        
       
         
          
         
  
      
        
       
  
     
       
       
      
      
   
         
           
          
  
  
randomized controlled trials, providing gold standard results. Second, a comprehensive search
strategy was used to identify all relevant articles. Third, several subgroup analyses were
performed to explore sources of heterogeneity. Fourth, the NutriGrade scoring system was 
used for quality assessment of included trials. Finally, the lack of significant asymmetry in the
funnel plots of studies suggested that our results are unlikely to be affected by publication 
bias.
Whilst there were a number of strengths, there are some limitations that may affect the results,
and must, therefore, be considered. The most important limitation of the present meta-
analysis is the small number of included studies that made the reliability of our conclusions 
unclear, this was, however, out of the operational control of the study. Furthermore, the IGFBPs
were not measured consistently across RCTs, which, consequently, limited our ability to
conduct analysis based on IGF/IGBP ratio. In addition, IGF-1 was measured as a secondary
outcome in most of the included studies which may reduce the statistical power to detect
significant effects. In addition, the regulatory effect of calcium and phosphate intake on the
endocrine actions of vitamin D was not well controlled across all of RCTs, which may 
conceivably have impacted our findings. 
Based on the limited evidence, it is not possible to draw any firm conclusions regarding the
effect of vitamin D supplementation on serum level of IGF-1. Therefore, it is pragmatic to
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Legends of Tables 
Table 1: Characteristics of trials that investigated the effect of vitamin D supplementation on
IGF-1 levels in adults and were eligible for inclusion in the meta-analysis 
Table 2: Meta-analysis showing the effect of vitamin D supplementation on serum levels of
























       
 





     
 
    
  
   
   
























   
 
       
 
   
 
  
   
  
 
   
  
    
      
  




















39, M & F 61.9 Italy GH deficiency No Vitamin D3 5000 
7000 
12 Significant increase in the
7000 IU group 
Kamycheva, 
2013 (27) 
318, M & F 49.2 Norway Overweight and
obese 
No Cholecalciferol 40 000 
20 000 
52 Significant increase in IGF-
1/IGFBP-3 ratio in subjects
























52 No significant change 
Sorva, 
1994 (37) 
55, M & F 84 Finland Bedridden elderly No Vitamin D3
and D2 
10002 40 No significant change 
Trummer, 
2017 (23) 
200, M & F 61 (int) 
60 (cont) 
Australia Hypertension Yes 
(<30 ng/ml) 
Vitamin D3 28001 8 No significant change 
Cont, control; F, Female; GH, Growth hormone, IGF, Insulin-like growth factor; IGFBP, Insulin-like growth factor binding protein; Int, intervention, M, Male 






                  
  
    
    
  
        
 
   
 
          
         
          
           
          
         
         
          
         
          
         
         
          
          
         
         
           
          
         
         
2Daily administration 
Table 2. Meta-analysis showing the effect of vitamin D supplementation on serum levels of IGF-1 (ng/ml) based on several subgroups (all analyses were conducted using random
effects model) 
Study group Studies (n) Participant 
s (n) 
Meta-analysis 
WMD (95%CI) P effect Q statistic 
Heterogeneity 




Overall 6 773 4.66 (-6.72, 16.03) 0.42 19.81 0.001 74.8 







5.42 (-6.57, 17.42) 























15.83 (-33.01, 64.89) 
-2.28 (-11.31, 6.75) 
-7.64 (-54.95, 39.67) 

























17.90 (-13.00, 48.80) 

















11.99 (-22.04, 46.02) 













          
           
          
         
            
           
           
         
          
          
           
         
         
         
          
         
         
           
          
          
         
            
          











22.35 (-12.69, 57.40) 

















5.43 (-6.57, 17.42) 




















-7.64 (-54.95, 39.67) 
15.83 (-33.01, 64.68) 




















17.63 (-6.67, 41.94) 










Type of vitamin D
Cholecalciferol, Vitamin D3 





4.66 (-6.72, 16.03) 

















-1.88 (-7.82, 4.06) 










BMI, Body mass index; IGF, Insulin-like growth factor; IU, International unit; WMD, Weighted mean difference. 
1Including growth hormone deficiency and hyperparathyroidism 












   
       
         
      






Legend of Figures 
Figure 1: Flow diagram for study selection process. 
Figure 2: Forest plot of randomized controlled clinical trials (RCTs) illustrating weighted mean
difference in serum levels of IGF-1 change (ng/ml) between the vitamin D supplementation






























































Records identified through 
database searching 














Records screened by title and 





Studies included in 
qualitative synthesis 
(n= 8) 




Full-text articles excluded, 
with reasons (n= 22)
Trials on children (n= 4)
Trials on pregnant women (n=
2)
Unsuitable in design (n=5)
Co-supplementation (n= 11)
































            
         
     
 
Figure 2: Forest plot of randomized controlled clinical trials (RCTs) illustrating weighted mean difference in serum
levels of IGF-1 change (ng/ml) between the vitamin D supplementation and control groups for all eligible studies. 
Analysis was conducted using random model effect.
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